Asia-Pacific Cardiac Sarcoidosis Market – Industry Trends and Forecast to 2030

 Asia-Pacific Cardiac Sarcoidosis Market Analysis and Size

Sarcoidosis is a multisystem inflammatory disease whose cause is unknown. Cardiac sarcoidosis is diagnosed in approximately 2-5% of patients with another systemic sarcoidosis; however, autopsies have revealed that cardiac sarcoidosis in the United States may be as high as 20-30%. African Americans have 3.8 times the prevalence of sarcoidosis as Caucasians in the United States and Asia-Pacific. The prevalence of cardiac sarcoidosis in Japanese patients may be as high as 58%, and it is the cause of death in 85% of sarcoid patients. Cardiovascular sarcoidosis has a poor prognosis, with patients frequently deteriorating rapidly.

Data Bridge Market Research analyses that the cardiac sarcoidosis market which was USD 16027.2 million in 2022, is expected to reach USD 46364.60 million by 2030, at a CAGR of 14.2% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Asia-Pacific Cardiac Sarcoidosis Market Scope and Segmentation      

Market Definition

Cardiac sarcoidosis is a rare inflammatory condition that causes immune cells to form granulomas in various areas of the heart, resulting in arrhythmias and heart failure. At this time, the causes of cardiac sarcoidosis are unknown. An immune system overreaction to an infectious agent (such as bacteria or viruses), chemical, or allergen may cause the disease.

Asia-Pacific Cardiac Sarcoidosis Market Dynamics

Drivers

• Rise in cardiovascular disease

Obesity among adults and youth is also on the rise, which is one of the leading causes of cardiovascular disease, fuelling market growth. As the prevalence of cardiovascular diseases increases, so does public health awareness, leading people to seek out simpler and more accessible diagnostics and treatment methods, such as simple cardiac monitoring devices. As a result of an increase in cardiovascular diseases during the forecast period, the market is expected to grow rapidly.

• Enhanced demand of cardiac sarcoidosis drugs and diagnosis

Corticosteroid therapy may slow the progression of cardiac disease and improve survival, but it appears to have no effect on the frequency of ventricular arrhythmias. 16 Steroids' mechanism of action in cardiac sarcoidosis is unknown, but it is thought that they can slow the progression of inflammation and fibrosis by re-establishing a normal TH1/TH2 balance. w32 Initially, prednisone doses of 60-80 mg per day are commonly prescribed. A starting dose of 30 mg/day was found to be sufficient in one study for improving prognosis. These are the specific factors for improving the diagnosis of cardiac sarcoidosis.

Opportunities

• Develop new and advanced cardiac sarcoidosis drugs

Scintigraphy using gallium-67 Gallium67 scintigraphy is also used to diagnose myocardial involvement caused by sarcoidosis. Because gallium67 only accumulates in active inflammatory areas, the test is only positive when the disease is active. Okayama and colleagues discovered that when thallium revealed myocardial defects, gallium heart uptake did not provide additional diagnostic information but was predictive of corticosteroid treatment efficacy.

Gallium single photon emission computed tomography (SPECT) scanning is frequently difficult to visualise abnormal nuclide uptake into the myocardium due to the inability to distinguish gallium uptake in other organs from that in the myocardium. Nakazawa and colleagues recently reported that dual SPECT using gallium67 and technetium99m can significantly improve the accuracy and spatial resolution of gallium67 SPECT scanning in the diagnosis of cardiac sarcoidosis.

Restraints/Challenges

• Antiarrhythmic treatment

Antiarrhythmic therapy and blockers are frequently used in the treatment of sarcoid heart disease. There have been no prospective studies evaluating the use of these agents in cardiac sarcoidosis patients. Blockers may increase the risk of heart block, and amiodarone may worsen restrictive lung disease in sarcoidosis. As a result, the doctor must carefully weigh the benefits and risks of prescribing these medications.

This cardiac sarcoidosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cardiac sarcoidosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2020, Mallinckrodt supported an awareness campaign launched by the American Lung Association (ALA) and the Foundation for Sarcoidosis Research (FSR) to empower sarcoidosis patients to fight such a chronic disease and take precautions against cardiac sarcoidosis. The company's public profile was raised as a result of the launch of this awareness campaign.
• In 2019, Hikma Pharmaceuticals PLC and Civica agreed to a five-year collaboration to address the generic drug shortage in the United States. The majority of medications used to treat cardiac sarcoidosis, including methotrexate, are available as generics. This agreement allowed the company to keep a steady supply of drugs on hand, allowing it to invest heavily in expanding its manufacturing capabilities.

Asia-Pacific Cardiac Sarcoidosis Market Scope

The cardiac sarcoidosis market is segmented on the basis of treatment, drugs type, inhibitors, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Diagnosis
• CT Scan
• PET
• ECG
• Others
• Drugs
• Methotrexate
• Corticosteroids
• Immunosuppressant Drugs
• Mycophenolate Mofetil
• Azathioprine
• Leflunomide
• Cyclophosphamide
• Others
• Antiarrhythmic Drugs
• Antimalarial Drugs
• Chloroquine
• Hydroxychloroquine
• Tumor Necrosis Factor-Alpha (Tnf-Alpha)

Inhibitors

• Adalimumab
• Infliximab
• Others

 Drugs Type

• Branded and Generic
• H.P. Acthar Gel
• Adempas
• Rayos
• Ofev
• Ara 290
• Others

Route of Administration

• Oral and Parenteral
• Intravenous
• Subcutaneous
• Others

 End User

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Cardiac Sarcoidosis Market Regional Analysis/Insights

The cardiac sarcoidosis market is analyzed and market size insights and trends are provided by country, treatment, drugs type, inhibitors, route of administration, end user and distribution channel as referenced above.

The countries covered in the cardiac sarcoidosis market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).

Japan is dominating the Asia-Pacific cardiac sarcoidosis market as the pharmaceutical industry is one of the top industries in the country with growing investors. Other important market factors include organic growth, changes in disposable income, and a focus on rapid urbanization.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The cardiac sarcoidosis market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cardiac sarcoidosis market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cardiac sarcoidosis market. The data is available for historic period 2011-2021.

Competitive Landscape and Cardiac Sarcoidosis Market Share Analysis

The cardiac sarcoidosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cardiac sarcoidosis market.

Some of the major players operating in the cardiac sarcoidosis market are:

• Hikma Pharmaceuticals PLC (U.K.)
• Mylan N.V. (U.S.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Mallinckrodt (U.K.)
• AbbVie Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Relief Therapeutics (Switzerland)
• Sandoz International GmbH (Switzerland)
• Teva Pharmaceuticals USA, INC. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• sanofi-aventis U.S. LLC (U.S.)
• Zydus Pharmaceuticals, Inc. (U.S.)
• Fresenius Kabi USA (U.S.)
• Merck & Co., Inc. (U.S.) 

SKU-54435